Literature DB >> 11263440

Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia.

A Tefferi, M A Elliot, S Y Yoon, C Y Li, R A Mesa, T G Call, A Dispenzieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11263440     DOI： 10.1182/blood.v97.6.1896

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

Review 1.  The therapy of myelofibrosis: targeting pathogenesis.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 3.  Myelofibrosis: an update on drug therapy in 2016.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

Review 4.  Modern management of splenomegaly in patients with myelofibrosis.

Authors:  Douglas Tremblay; Myron Schwartz; Richard Bakst; Rahul Patel; Thomas Schiano; Marina Kremyanskaya; Ronald Hoffman; John Mascarenhas
Journal:  Ann Hematol       Date:  2020-05-17       Impact factor: 3.673

Review 5.  Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.

Authors:  Ruben A Mesa; Alfonso Quintás-Cardama; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

6.  The prediction of interferon treatment effects based on time series microarray gene expression profiles.

Authors:  Tao Huang; Kang Tu; Yu Shyr; Chao-Chun Wei; Lu Xie; Yi-Xue Li
Journal:  J Transl Med       Date:  2008-08-09       Impact factor: 5.531

7.  Management of thrombocythemia.

Authors:  Krisstina Gowin; Ruben Mesa
Journal:  F1000Res       Date:  2014-09-29

Review 8.  Profile of pomalidomide and its potential in the treatment of myelofibrosis.

Authors:  Krisstina L Gowin; Ruben A Mesa
Journal:  Ther Clin Risk Manag       Date:  2015-04-02       Impact factor: 2.423

Review 9.  Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.

Authors:  Andrew L Sochacki; Melissa A Fischer; Michael R Savona
Journal:  Onco Targets Ther       Date:  2016-04-15       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.